Table 1.
Demographic and treatment characteristics of study participants
| |
Subject group |
|||||
|---|---|---|---|---|---|---|
| |
CD4 < 250 |
CD4 > 500 |
ART (PI/r) |
ART (NNRTI) |
HIV- |
p-value |
| n = 22 | n = 22 | n = 24 | n = 23 | n = 92 | – | |
| Sex (male:female) |
12:10 |
16:6 |
11:13 |
18:5 |
56:36 |
ns |
| Age in years |
36 (22–61) |
45 (20–73) |
41 (21–65) |
46 (27–62) |
44 (20–73) |
ns |
| Months since HIV-diagnosis |
0 (0–101) |
30 (3–207) |
152 (32–305) |
155 (50–302) |
– |
*** |
| CD4 nadir (× 106 cells/l) |
170 (30–250) |
480 (300–1000) |
175 (0–310) |
150 (0–470) |
– |
*** |
| CD4 at baseline (× 106 cells/l) |
170 (40–250) |
605 (520–1000) |
565 (360–1100) |
470 (270–900) |
– |
*** |
| HIV RNA (log10 copies/ml) |
4.89 (2.89–5.93) |
3.87 (< 1.28–5.12) |
All < 1.28 |
All < 1.28 |
– |
*** |
| Pre-ART HIV RNA (log10 copies/ml) |
– |
– |
5.05 (2.63–6.62) |
4.88 (2.92–5.79) |
– |
** |
| Treatment duration (months) |
– |
– |
57 (28–204) |
77 (28–210) |
– |
ns |
| Apolipoprotein B (g/L) |
0.81 (0.47–1.40) |
0.92 (0.47–1.40) |
1.10 (0.33–1.50) |
1.00 (0.47–1.80) |
0.87 (0.42–2.20) |
* |
| Apolipoprotein A1 (g/L) |
1.40 (0.76–2.10) |
1.45 (0.94–1.90) |
1.55 (1.10–1.90) |
1.70 (1.10–2.80) |
1.50 (1.10–2.60) |
ns |
| Total cholesterol (mmol/L) |
4.2 (3.0–8.4) |
5.0 (3.6–7.1) |
5.7 (2.4–7.8) |
6.0 (3.6–9.5) |
– |
*** |
| HDL-cholesterol (mmol/L) |
1.3 (0.6–2.1) |
1.3 (0.6–2.1) |
1.2 (0.9–2.0) |
1.5 (0.9–2.7) |
– |
ns |
| Triglycerides (mmol/L) |
1.20 (0.49–4.30) |
1.45 (0.50–2.50) |
2.15 (0.78–9.40) |
1.70 (0.71–12.00) |
– |
** |
| hsCRP (mg/L) |
2.75 (0.17–50.00) |
1.60 (0.00–12.00) |
1.40 (0.00–14.00) |
3.50 (0.34–11.00) |
0.63 (0.0–36.00) |
*** |
| Soluble CD14 (ng/mL) | 1333 (991–3762) | 1491 (842–1888) | 1621 (1067–2283) | 1796 (1228–3528) | 1259 (872–2131) | *** |
Significance testing was performed for all five groups where data was available for HIV- controls, otherwise only for HIV + subjects. ART: antiretroviral treament; PI/r: ritonavir-boosted protease inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; hsCRP: highly sensitivity C-reactive protein. All values are given as median (range). NS: not significant; *p < 0.05; **p < 0.01; ***p < 0.001.